Levopront

Levodropropizine, the active ingredient in Levopront, is a peripheral antitussive presented as an oral formulation for oral use. It reduces the cough reflex by acting on sensory C‑fibers in the respiratory tract and is indicated for the symptomatic relief of cough in adults and children when a non‑opioid option is preferred.

GNH USA supplies Levopront as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Levodropropizine is used as a peripheral antitussive to manage cough arising from irritation of the respiratory tract.

- Acute cough: provides symptomatic relief by decreasing cough reflex sensitivity. - Chronic cough: helps control persistent coughing when non‑opioid therapy is desired. - Cough associated with upper respiratory tract infection: reduces frequency and severity of cough without central nervous system effects. - Cough due to allergic rhinitis: alleviates cough triggered by post‑nasal drip.

Levodropropizine is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Nausea: mild stomach upset that may occur after dosing. - Dry mouth: reduced salivation leading to a feeling of thirst. - Headache: transient head discomfort. - Dizziness: light‑headed sensation, especially on standing. - Abdominal discomfort: mild stomach pain or cramps.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling that may require medical attention. - Angioedema: rapid swelling of face, lips, or tongue, a medical emergency. - Hepatic enzyme elevation: abnormal liver function tests indicating possible liver involvement.

When prescribing Levodropropizine, consider the following precautions to ensure safe use.

- Contraindication: avoid use in patients with known hypersensitivity to levodropropizine or any excipients. - Caution in hepatic impairment: monitor liver function as the drug is metabolized hepatically. - Use in children: dosage and safety should be determined by a pediatric specialist. - Pregnancy and lactation: limited data; use only if potential benefit outweighs risk. - Drug interactions: review concomitant medications that may affect cough reflex or hepatic metabolism. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Levodropropizine may interact with other medicines; careful review is advised.

Major Interactions (Avoid): - Combined use with other opioid‑containing antitussives (e.g., codeine, dextromethorphan): risk of additive central effects. - Strong CYP450 inhibitors (if metabolized via CYP pathways): may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance antitussive effect, requiring symptom monitoring. - Bronchodilators: monitor for altered perception of cough. - Concurrent hepatotoxic drugs: observe liver function tests periodically.